Market research
BOT.AU Botanix Pharmaceuticals Limited
AU AUD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 33M
- P/E ratio
- Not available
- Analyst target
- 0.4833
- Dividend yield
- Not available
- Beta
- 0.86
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000BOT2
- Market cap
- 33M
- P/E ratio
- Not available
- Analyst target
- 0.4833
- Dividend yield
- Not available
- Beta
- 0.86
About
About Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used to treat underarm sweating in adults and children 9 years of age and older. It also develops BTX 1503, a transdermal gel formulation, which is in Phase 3 clinical trial for the treatment of serious acne in adults and teenagers; BTX 1702 that is in Phase 1b/2 clinical trial to treat papulopustular rosacea; BTX 1204A for treating atopic dermatitis; and BTX 1801, which has been completed Phase 2a clinical trial for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus. The company was incorporated in 1984 and is based in Melbourne, Australia.
Research context
Botanix Pharmaceuticals Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the BOT.AU discussion.
5 years, 6 months ago
Botanix Pharmaceuticals Limited is currently in a long term downtrend where the price is trading 19.6% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Botanix Pharmaceuticals Limited's total revenue sank by 14.4% to $89K since the same quarter in the previous year.
Its net income has increased by 109.5% to $664K since the same quarter in the previous year.
Finally, its free cash flow grew by 63.6% to $-3M since the same quarter in the previous year.
Based on the above factors, Botanix Pharmaceuticals Limited gets an overall score of 3/5.